UNSPSC 51333416: Ziprasidone mesilate or mesylate

This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS.CH4O3S.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X6SAX83JZ, chemically known as 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, methanesulfonate, hydrate (1:1:3), but more generally known as ziprasidone mesylate, which bears US NIH Compound Identifier 154068.

European Medicines Agency schedules ziprasidone mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00168MIG. Most nations, for tariff purposes, schedule ziprasidone mesylate under HS 29341000. Ziprasidone mesylate bears US NLM identifiers UMLS ID C1170754 and NCI Concept Code C48032. SMILES: CS(=O)(=O)O.C1CCC2C(C1)C(NS2)N3CCN(CC3)CCC4CC5C(CC4CL)NC(=O)C5.O.O.O.

UNSPSC 51333416 Ziprasidone mesilate or mesylate is a Commodity code that shows minimal alignment with recent state and local procurement activity. The code nominally describes a specific atypical antipsychotic pharmaceutical, but the three most recent opportunities posted under or near this classification involve naloxone and drug deactivation systems, a direct-to-manufacturer pharmacy initiative RFI, and a multistate cooperative purchasing agreement for generic multi-source pharmaceuticals and OTC products—none of which map to ziprasidone procurement specifically. State and local solicitation activity under this code does not reflect purchases of the named pharmaceutical itself.

The geographic spread of recent opportunities includes Florida (Seminole County), Texas (HHS Commission), and Minnesota (MMCAP, serving multiple states including Oregon). The single opportunity with apparent topical relevance—Seminole County's IFB60459723LAS, posted June 30, 2026, with response due July 26, 2026—concerns naloxone and drug deactivation systems for community health support, not antipsychotic medications. The Texas HHS RFI (HHS0017013, posted April 3, 2026) explores direct-to-manufacturer prescription programs but does not name specific drugs. The Minnesota MMCAP RFP (S1070000015802, posted January 20, 2026, response due March 26, 2026) establishes cooperative contracts for generic pharmaceuticals and OTC products across state and local government facilities, with awards effective July 1, 2026, but does not isolate ziprasidone as a line item. The code shows little relevant recent activity; misalignment between the UNSPSC category name and the posted opportunities suggests either miscoding in state and local systems or minimal current procurement demand for ziprasidone mesilate through state and local channels.